Drug-induced liver injury in obesity and nonalcoholic fatty liver disease.
Allard J, Le Guillou D, Begriche K, Fromenty B.
Adv Pharmacol. 2019;85:75-107. doi: 10.1016/bs.apha.2019.01.003. Epub 2019 Feb 20.
Drug-Induced Intracranial Hypertension: A Systematic Review and Critical Assessment of Drug-Induced Causes.
Tan MG, Worley B, Kim WB, Ten Hove M, Beecker J.
Am J Clin Dermatol. 2020 Apr;21(2):163-172. doi: 10.1007/s40257-019-00485-z.
A Review on Drug Induced Obesity and Rodent Experimental Models of Obesity in Animals.
Vangoori Y, Suresh BS, Midde ML, Anusha D, Uppala PK.
Maedica (Bucur). 2022 Sep;17(3):706-713. doi: 10.26574/maedica.2022.17.3.706.
Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options.
Verhaegen AA, Van Gaal LF.
J Endocrinol Invest. 2017 Nov;40(11):1165-1174. doi: 10.1007/s40618-017-0719-6. Epub 2017 Jun 28.
Drug-induced liver injury in obesity.
Fromenty B.
J Hepatol. 2013 Apr;58(4):824-6. doi: 10.1016/j.jhep.2012.12.018. Epub 2013 Jan 5.
Drug-Induced Mitochondrial Toxicity.
Hargreaves IP, Al Shahrani M, Wainwright L, Heales SJ.
Drug Saf. 2016 Jul;39(7):661-74. doi: 10.1007/s40264-016-0417-x.
Decreased 5-HT2cR and GHSR1a interaction in antipsychotic drug-induced obesity.
Huang XF, Weston-Green K, Yu Y.
Obes Rev. 2018 Mar;19(3):396-405. doi: 10.1111/obr.12638. Epub 2017 Nov 9.
Drug-Induced Sleep Endoscopy Findings in Children With Obstructive Sleep Apnea With vs Without Obesity or Down Syndrome.
Hyzer JM, Milczuk HA, Macarthur CJ, King EF, Quintanilla-Dieck L, Lam DJ.
JAMA Otolaryngol Head Neck Surg. 2021 Feb 1;147(2):175-181. doi: 10.1001/jamaoto.2020.4548.
Inflammation and resolution in obesity.
Soták M, Clark M, Suur BE, Börgeson E.
Nat Rev Endocrinol. 2025 Jan;21(1):45-61. doi: 10.1038/s41574-024-01047-y. Epub 2024 Oct 24.
Drug-induced metabolic syndrome.
Wofford MR, King DS, Harrell TK.
J Clin Hypertens (Greenwich). 2006 Feb;8(2):114-9. doi: 10.1111/j.1524-6175.2006.04751.x.
